Glucagonoma and the glucagonoma syndrome - Cumulative experience with an elusive endocrine tumour

Clinical Endocrinology

Volumn 74, Issue 5, 2011, Pages 593-598

  Eldor, Roy ^a,c   Glaser, Benjamin ^a   Fraenkel, Merav ^a   Doviner, Victoria ^b   Salmon, Asher ^b   Gross, David J ^a  

^a Medical Center   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 PHENYLALANINE 3 TYROSINE OCTREOTIDE Y 90; ANGIOPEPTIN; CHELATING AGENT; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GLUCAGON; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; ENDOCRINE TUMOR; FEMALE; FOLLOW UP; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; HUMAN; LIVER METASTASIS; MALE; METASTASIS; NECROLYTIC MIGRATORY ERYTHEMA; NEUROENDOCRINE TUMOR; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL; SKIN BIOPSY; SURVIVAL RATE; THROMBOSIS; WEAKNESS; WEIGHT REDUCTION;

ENDOCRINE GLAND NEOPLASMS; GLUCAGONOMA; HUMANS; MIDDLE AGED; NECROLYTIC MIGRATORY ERYTHEMA; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SOMATOSTATIN; SURVIVAL RATE; SYNDROME; TREATMENT OUTCOME;

EID: 79953735653     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.03967.x     Document Type: Article

References (35)

1. Wermers, R.A., Fatourechi, V., Wynne, A.G., et al. (1996) The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore), 75, 53-63. (Pubitemid 26112227)
2. Soga, J., &, Yakuwa, Y., (1998) Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. Journal of Hepatobiliary Pancreatic Surgery, 5, 312-319. (Pubitemid 128662599)
3. Tierney, E.P., &, Badger, J., (2004) Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. Medscape General Medicine, 6, 4.
4. Koike, N., Hatori, T., Imaizumi, T., et al. (2003) Malignant glucagonoma of the pancreas diagnoses through anemia and diabetes mellitus. Journal of Hepatobiliary Pancreatic Surgery, 10, 101-105. (Pubitemid 36850312)
5. Fenkci, S.M., Fidan Yaylali, G., Sermez, Y., et al. (2005) Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update. Endocrine-Related Cancer, 12, 449-454. (Pubitemid 40896458)
6. McGevna, L., McFadden, D., Ritvo, J., et al. (2009) Glucagonoma- associated neuropsychiatric and affective symptoms: diagnostic dilemmas raised by paraneoplastic phenomena. Psychosomatics, 50, 548-550.
7. Chang-Chretien, K., Chew, J.T., &, Judge, D.P., (2004) Reversible dilated cardiomyopathy associated with glucagonoma. Heart, 90, e44.
8. de Mestier, L., Hammel, P., Hentic, O., et al. (2010) Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency. Gastroenterologie Clinique et Biologique, 34, 106-110.
9. Case, C.C., &, Vassilopoulou-Sellin, R., (2003) Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia. Endocrine Practice, 9, 22-25. (Pubitemid 36790107)
10. van Beek, A.P., de Haas, E.R., van Vloten, W.A., et al. (2004) The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. European Journal of Endocrinology, 151, 531-537.
11. DeLellis, R., Lloyd, R., &, Heitz, P., (2004) World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs. IARC, Lyon.
12. Yao, J.C., Eisner, M.P., Leary, C., et al. (2007) Population-based study of islet cell carcinoma. Annals of Surgical Oncology, 14, 3492-3500. (Pubitemid 350160130)
13. Butte, J.M., Montero, P.H., Solar, A., et al. (2008) Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: report of a case. Surgery Today, 38, 1137-1143.
14. Anlauf, M., Schlenger, R., Perren, A., et al. (2006) Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. American Journal of Surgical Pathology, 30, 560-574. (Pubitemid 44265008)
15. Pinto Marin, A., Hernandez Agudo, E., Feliu, J., et al. (2009) Pancreatic glucagonoma presenting as a pulmonary mass. Clinical and Translational Oncology, 11, 60-62.
16. Dourakis, S.P., Alexopoulou, A., Georgousi, K.K., et al. (2007) Glucagonoma syndrome: survival 21 years with concurrent liver metastases. American Journal of the Medical Sciences, 334, 225-227. (Pubitemid 47415000)
17. Chu, Q., Al-Kasspooles, M., Smith, J., et al. (2001) Is glucagonoma of the pancreas a curable disease? International Journal of Gastrointestinal Cancer, 29, 155-162.
18. Vauleon, E., Egreteau, J., Boucher, E., et al. (2004) Glucagonoma: a recent series of 7 cases. Bulletin du Cancer, 91, 637-640. (Pubitemid 39158741)
19. Kindmark, H., Sundin, A., Granberg, D., et al. (2007) Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Medical Oncology, 24, 330-337. (Pubitemid 350135956)
20. Recant, L., Perrino, P.V., Bhathena, S.J., et al. (1976) Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased "large glucagon-immunoreactivity". Diabetologia, 12, 319-326.
21. Rindi, G., Kloppel, G., Alhman, H., et al. (2006) TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 449, 395-401. (Pubitemid 44451313)
22. Kitamura, Y., Sato, M., Hatamochi, A., et al. (2005) Necrolytic migratory erythema without glucagonoma associated with hepatitis B. European Journal of Dermatology, 15, 49-51. (Pubitemid 40254625)
23. Technau, K., Renkl, A., Norgauer, J., et al. (2005) Necrolytic migratory erythema with myelodysplastic syndrome without glucagonoma. European Journal of Dermatology, 15, 110-112. (Pubitemid 40434639)
24. Zhang, M., Xu, X., Shen, Y., et al. (2004) Clinical experience in diagnosis and treatment of glucagonoma syndrome. Hepatobiliary & Pancreatic Diseases International, 3, 473-475. (Pubitemid 39173089)
25. Echenique-Elizondo, M., Tuneu Valls, A., Elorza Orue, J.L., et al. (2004) Glucagonoma and pseudoglucagonoma syndrome. Journal of Pancreas, 5, 179-185. (Pubitemid 41573865)
26. Liu, W.J., Zhao, Y.P., Zhang, T.P., et al. (2009) Clinical experience in diagnosis and treatment of glucagonoma. Zhonghua Wai Ke Za Zhi, 47, 333-336.
27. Akerstrom, G., Hellman, P., Hessman, O., et al. (2004) Surgical treatment of endocrine pancreatic tumours. Neuroendocrinology, 80 (Suppl 1), 62-66. (Pubitemid 39382372)
28. Appetecchia, M., Ferretti, E., Carducci, M., et al. (2006) Malignant glucagonoma. New options of treatment. Journal of Experimental & Clinical Cancer Research, 25, 135-139.
29. Arnold, R., Wied, M., &, Behr, T.H., (2002) Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opinion on Pharmacotherapy, 3, 643-656. (Pubitemid 34649694)
30. Rosenbaum, A., Flourie, B., Chagnon, S., et al. (1989) Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion, 42, 116-120. (Pubitemid 19151335)
31. Alexander, E.K., Robinson, M., Staniec, M., et al. (2002) Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clinical Endocrinology (Oxford), 57, 827-831. (Pubitemid 36963011)
32. van Essen, M., Krenning, E.P., Kam, B.L., et al. (2009) Peptide-receptor radionuclide therapy for endocrine tumors. Nature Reviews. Endocrinology, 5, 382-393.
33. Kwekkeboom, D.J., Kam, B.L., van Essen, M., et al. (2010) Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer, 17, R53-R73.
34. Kwekkeboom, D.J., de Herder, W.W., Kam, B.L., et al. (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology, 26, 2124-2130.
35. Muros, M.A., Varsavsky, M., Iglesias Rozas, P., et al. (2009) Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Clinical and Translational Oncology, 11, 48-53.